Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Gross Profit (2016 - 2025)

Historic Gross Profit for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $14.0 million.

  • Lifecore Biomedical, Inc. \De\'s Gross Profit fell 1904.82% to $14.0 million in Q2 2025 from the same period last year, while for May 2025 it was $40.3 million, marking a year-over-year decrease of 371.08%. This contributed to the annual value of $40.3 million for FY2025, which is 370.85% down from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s Gross Profit stood at $14.0 million, which was down 1904.82% from $9.8 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Gross Profit high stood at $17.3 million for Q2 2024, and its period low was $2.7 million during Q3 2023.
  • Moreover, its 5-year median value for Gross Profit was $10.2 million (2022), whereas its average is $9.7 million.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Gross Profit tumbled by 5437.36% in 2023 and then soared by 12203.37% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Gross Profit stood at $11.5 million in 2021, then tumbled by 50.44% to $5.7 million in 2022, then soared by 75.33% to $10.0 million in 2023, then increased by 11.32% to $11.1 million in 2024, then increased by 26.15% to $14.0 million in 2025.
  • Its last three reported values are $14.0 million in Q2 2025, $9.8 million for Q1 2025, and $11.1 million during Q4 2024.